Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus
暂无分享,去创建一个
M. Kiso | Y. Kawaoka | I-Hsuan Wang | A. Yasuhara | S. Yamayoshi | S. Yamada | M. Koga | E. Adachi | Y. Sakai-Tagawa | T. Kikuchi
[1] David J. Topham,et al. Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies , 2018, Cell.
[2] Y. Kawaoka,et al. Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human. , 2017, The Journal of infection.
[3] Y. Kawaoka,et al. Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies , 2017, Scientific Reports.
[4] S. Subramaniam,et al. Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes , 2017, Nature Microbiology.
[5] M. Kiso,et al. A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release , 2017, EBioMedicine.
[6] Zhu Guo,et al. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo. , 2016, Antiviral research.
[7] J. Powers,et al. Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model , 2016, mBio.
[8] P. Wilson,et al. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. , 2016, The Journal of clinical investigation.
[9] A. Monto,et al. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. , 2015, The Journal of infectious diseases.
[10] M. Eichelberger,et al. Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase , 2015, Journal of Virology.
[11] J. Ravetch,et al. The role of Fc–FcγR interactions in IgG-mediated microbial neutralization , 2015, The Journal of experimental medicine.
[12] M. Eichelberger,et al. Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers , 2015, Nature Communications.
[13] M. Eichelberger,et al. An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. , 2014, Journal of virological methods.
[14] J. Ravetch,et al. Type I and type II Fc receptors regulate innate and adaptive immunity , 2014, Nature Immunology.
[15] Antoine M. van Oijen,et al. Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization , 2013, PloS one.
[16] Szabina Fodor,et al. Neutrophil cell surface receptors and their intracellular signal transduction pathways , 2013, International immunopharmacology.
[17] A. Mantovani,et al. Serum Amyloid P Is a Sialylated Glycoprotein Inhibitor of Influenza A Viruses , 2013, PloS one.
[18] Luigi Calzolai,et al. Rational Engineering of a Human Anti-Dengue Antibody through Experimentally Validated Computational Docking , 2013, PloS one.
[19] N. S. Laursen,et al. Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.
[20] Ryo Takano,et al. Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. , 2011, Virus research.
[21] Eiryo Kawakami,et al. Seroprevalence of Pandemic 2009 (H1N1) Influenza A Virus among Schoolchildren and Their Parents in Tokyo, Japan , 2011, Clinical and Vaccine Immunology.
[22] J. Yewdell,et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection , 2011, The Journal of Experimental Medicine.
[23] Albert D. M. E. Osterhaus,et al. Recombinant Soluble, Multimeric HA and NA Exhibit Distinctive Types of Protection against Pandemic Swine-Origin 2009 A(H1N1) Influenza Virus Infection in Ferrets , 2010, Journal of Virology.
[24] K. Ikuta,et al. Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors , 2009, Biochemical and Biophysical Research Communications.
[25] A. Fomsgaard,et al. The evolution of human influenza A viruses from 1999 to 2006: A complete genome study , 2008, Virology Journal.
[26] J. Skehel,et al. Variation and infectivity neutralization in influenza , 2006, Immunology.
[27] Guang-Wu Chen,et al. Genomic Signatures of Human versus Avian Influenza A Viruses , 2006, Emerging infectious diseases.
[28] Sang Joon Kim,et al. A Mathematical Theory of Communication , 2006 .
[29] H. Klenk,et al. Neuraminidase Is Important for the Initiation of Influenza Virus Infection in Human Airway Epithelium , 2004, Journal of Virology.
[30] A. Dalton,et al. An Electron Microscope Study , 2003 .
[31] J. Taubenberger,et al. Influenza A virus neuraminidase: regions of the protein potentially involved in virus-host interactions. , 2000, Virology.
[32] J. Skehel,et al. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. , 2000, Annual review of biochemistry.
[33] Tokiko Watanabe,et al. Generation of influenza A viruses entirely from cloned cDNAs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[34] I. Mellman,et al. Human IgG Fc receptor (hFcRII; CD32) exists as multiple isoforms in macrophages, lymphocytes and IgG‐transporting placental epithelium. , 1989, The EMBO journal.
[35] S. Cusack,et al. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid , 1988, Nature.
[36] G. Air,et al. Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase. , 1985, Virology.
[37] L. Gerace,et al. Phosphorylation of the nuclear lamins during interphase and mitosis. , 1985, The Journal of biological chemistry.
[38] J. Oxford,et al. An investigation of antigenic drift of neuraminidases of influenza A (H1N1) viruses , 1984, Journal of Hygiene.
[39] J. N. Varghese,et al. Structure of the catalytic and antigenic sites in influenza virus neuraminidase , 1983, Nature.
[40] G. Trinchieri,et al. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. , 1983, Journal of immunology.
[41] G. Air,et al. Amino acid sequence changes in antigenic variants of type A influenza virus N2 neuraminidase. , 1982, Virology.
[42] W G Laver,et al. Molecular mechanisms of variation in influenza viruses , 1982, Nature.
[43] I. Wilson,et al. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution , 1981, Nature.
[44] C W Potter,et al. Determinants of immunity to influenza infection in man. , 1979, British medical bulletin.
[45] R. Compans,et al. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. , 1974, Virology.
[46] A. Monto,et al. Effect of neuraminidase antibody on Hong Kong influenza. , 1973, Lancet.
[47] A. S. Beare,et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.
[48] R. Chanock,et al. Association of serum anti-neuraminidase antibody with resistance to influenza in man. , 1972, The New England journal of medicine.
[49] F. S. Chang,et al. Functional Significance of Sialidase During Influenza Virus Multiplication: an Electron Microscope Study , 1969, Journal of virology.
[50] E. D. Kilbourne,et al. Protective Effects of Specific Immunity to Viral Neuraminidase on Influenza Virus Infection of Mice , 1968, Journal of virology.
[51] R. Webster,et al. Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. , 1967, Journal of immunology.